ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

PLX Protalix BioTherapeutics Inc

1.16
0.06 (5.45%)
Last Updated: 18:37:57
Delayed by 15 minutes
Share Name Share Symbol Market Type
Protalix BioTherapeutics Inc AMEX:PLX AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.06 5.45% 1.16 1.16 1.12 1.13 259,161 18:37:57

Form 424B3 - Prospectus [Rule 424(b)(3)]

07/07/2023 9:30pm

Edgar (US Regulatory)


Prospectus Supplement No. 1

(To Prospectus Dated April 29, 2020)

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-237736

 

 

 

Common Stock

 

This Prospectus Supplement supplements, and should be read in conjunction with, our Prospectus included in Registration Statement on Form S-3 (Registration No. 333-237736) dated April 29, 2020 (the “Prospectus”). This Prospectus Supplement must be delivered with the Prospectus.

 

The information in the Prospectus in the section titled “Selling Stockholders” is amended by this Prospectus Supplement to reflect the transfer by Highbridge Tactical Credit Master Fund, L.P. of a warrant to purchase 489,938 shares of our common stock to Highbridge Tactical Credit Institutional Fund, Ltd.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this Prospectus Supplement. Any representation to the contrary is a criminal offense.

 

 

The date of this Prospectus Supplement is July 7, 2023.

 

SELLING STOCKHOLDERS

SUPPLEMENTAL INFORMATION

 

The table beginning on page 8 of the Prospectus in the section titled “Selling Stockholders” is amended as follows.

 

The table is hereby revised to reflect the following transfer: Highbridge Tactical Credit Master Fund, L.P. transferred warrants to purchase 489,938 shares of our common stock to Highbridge Tactical Credit Institutional Fund, Ltd. The beneficial ownership information for the selling stockholder listed below is as of July 1, 2023 and is based on 71,580,762 shares outstanding as of such date.

 

    Shares of Common Stock Beneficially Owned Prior to the Offering     Shares of Common Stock Being Offered Hereby     Shares of Common Stock Beneficially Owned
After Completion of the Offering
 
Name of Selling Stockholder   Number     Percent     Number     Number     Percent  
Highbridge Tactical Credit Master Fund, L.P. (1)(2)     1,923,549       2.7%       1,923,549       -       -  
Highbridge Tactical Credit Institutional Fund, Ltd. (1)(2)     489,938       0.7%       489,938       -       -  

 

(1) Highbridge Capital Management, LLC, a Delaware limited liability company, serves as the investment adviser to both Highbridge Tactical Credit Master Fund, L.P. and Highbridge Tactical Credit Institutional Fund, Ltd.

(2) Does not include shares of our common stock issuable upon conversion of our outstanding 7.50% Senior Secured Convertible Promissory Notes Due September 2024 held by Highbridge Tactical Credit Master Fund, L.P.

 

 


1 Year Protalix BioTherapeutics Chart

1 Year Protalix BioTherapeutics Chart

1 Month Protalix BioTherapeutics Chart

1 Month Protalix BioTherapeutics Chart